"While overall very reasonable, this still comes at a cost in terms of significant toxicity, not to mention the cost of additional treatment," Dr. Edelman observed. "We really need a cost-effectiveness analysis in this era to follow strategies of frequent visits and scanning with early institution of second-line therapy versus the maintenance approach."
Eli Lilly funded the study. Dr. Paz-Ares disclosed no relevant relationships. Several coauthors reported relationships with industry, including employment, stock ownership, honoraria, and consultancy with Lilly, which markets pemetrexed.